Search research articles
Contact Us
Filters
Showing results (781-790 of 819) with videos related to
Page
of 82
Sort By:
Molecular Cancer Therapeutics
|
September 29, 2018
Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer
Tilman Todenhöfer, Roland Seiler, Craig Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Urologia Internationalis
|
July 28, 2016
Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma
Georgios Gakis, Jason A Efstathiou, Siamak Daneshmand, et al.
Urologic Oncology
|
March 23, 2020
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial
Natalya Benderska-Söder, Jan Hovanec, Beate Pesch, et al.
World Journal of Urology
|
April 3, 2014
Is there an anti-androgen withdrawal syndrome for enzalutamide?
Christoph A J von Klot, Mario W Kramer, Alena Böker, et al.
European Urology
|
February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
Shilpa Gupta, Roger Li, Patrick J Hensley, et al.
European Urology Oncology
|
June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy
Stefano Fanti, Alberto Briganti, Louise Emmett, et al.
European Urology
|
January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J Motzer, Paul Russo, Naomi Haas, et al.
Nature Communications
|
November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identification
Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Genome Medicine
|
September 15, 2022
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Florian A Büttner, Stefan Winter, Viktoria Stühler, et al.
Page
of 82
Search research articles
Search
Showing results (781-790 of 819) with videos related to
Sort By:
Page
of 82
Molecular Cancer Therapeutics
|
September 29, 2018
Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer
Tilman Todenhöfer, Roland Seiler, Craig Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Urologia Internationalis
|
July 28, 2016
Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma
Georgios Gakis, Jason A Efstathiou, Siamak Daneshmand, et al.
Urologic Oncology
|
March 23, 2020
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial
Natalya Benderska-Söder, Jan Hovanec, Beate Pesch, et al.
World Journal of Urology
|
April 3, 2014
Is there an anti-androgen withdrawal syndrome for enzalutamide?
Christoph A J von Klot, Mario W Kramer, Alena Böker, et al.
European Urology
|
February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
Shilpa Gupta, Roger Li, Patrick J Hensley, et al.
European Urology Oncology
|
June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy
Stefano Fanti, Alberto Briganti, Louise Emmett, et al.
European Urology
|
January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J Motzer, Paul Russo, Naomi Haas, et al.
Nature Communications
|
November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identification
Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Genome Medicine
|
September 15, 2022
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Florian A Büttner, Stefan Winter, Viktoria Stühler, et al.
Page
of 82